Syros Pharmaceuticals, Inc. (NASDAQ:SYRS – Get Free Report) shares crossed above its fifty day moving average during trading on Monday . The stock has a fifty day moving average of $0.00 and traded as high as $0.0004. Syros Pharmaceuticals shares last traded at $0.0004, with a volume of 84,828 shares.
Syros Pharmaceuticals Stock Performance
The company has a market cap of $10,732.80, a price-to-earnings ratio of -0.00 and a beta of 1.31.
About Syros Pharmaceuticals
Syros Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company headquartered in Cambridge, Massachusetts, that is pioneering a new class of targeted therapeutics by focusing on the control of gene expression. Founded in 2015 as a spin-out from the Broad Institute, Syros leverages its proprietary gene control platform to identify and drug key noncoding regions of the genome that regulate disease-driving genes. The company’s approach aims to convert previously undruggable gene targets into precise medicines for patients with cancer and rare genetic disorders.
Syros’ lead development candidate, tamibarotene (SY-1425), is an oral, selective RARα agonist being evaluated in acute myeloid leukemia (AML) and high-risk myelodysplastic syndromes (MDS) characterized by RARA dependence.
Featured Articles
- Five stocks we like better than Syros Pharmaceuticals
- Striking Oil: How the U.S. Play for Venezuela Fuels Supermajors
- J.M. Smucker Stock’s Rally Has More Than Tariffs Behind It
- Wendy’s Rally Fades After Trian Steps Back: Was It Ever Real?
- GitLab’s Earnings Beat Just Gave Software Bulls a New SaaSpocalypse Test
Receive News & Ratings for Syros Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Syros Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
